ACM
GYRE icon

AIGH Capital Management’s Gyre Therapeutics GYRE Stock Holding History

AIGH Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-56,139
Closed -$2.66M – 54
2020
Q4 		$2.66M Buy
+56,139
New +$2.43M 1.08% 25

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

AIGH Capital Management's GYRE Position: Q1 2021 in Review

AIGH Capital Management sold out of Gyre Therapeutics (GYRE) in Q1 2021, closing a stake of 56,139 shares — an estimated $2.66M sold.

AIGH Capital Management first reported a position in GYRE in Q4 2020 and held it in 1 quarter. The position peaked at $2.66M in Q4 2020. 89 funds tracked by Wall St. Rank hold GYRE as of Q1 2021.

  • AIGH Capital Management reported no remaining Gyre Therapeutics position as of Q1 2021 after selling out during the quarter.
  • AIGH Capital Management sold 56,139 Gyre Therapeutics shares in Q1 2021, an estimated $2.66M.
  • AIGH Capital Management first reported a position in Gyre Therapeutics in Q4 2020 and held it in 1 quarter.
  • AIGH Capital Management's Gyre Therapeutics position peaked at $2.66M in Q4 2020.
  • 89 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2021.

Based on AIGH Capital Management's 13F filing for Q1 2021, filed 13 May 2021.